Free Cash Flow

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

With a record $1.2B order backlog and a bullish 2026 forecast, the specialty vehicle maker also announces a major leadership shift to drive its next growth phase.

The coffee giant posts impressive 2025 results amid high inflation, paving the way for its blockbuster acquisition by Keurig Dr Pepper. What's next?

With overwhelming bondholder support, the media giant gains financial flexibility for shareholder returns while tightening protections for its creditors.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Following strong earnings and a major SAP settlement, Teradata will detail its AI-driven future and financial outlook at two key investor conferences.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

The company's revenue skyrocketed, but SEC filings reveal a story of significant liquidity risks and a bold gamble on the booming wellness market.

A landmark partnership between Grassroots Carbon and Colorado State University is set to validate soil carbon removal, impacting ranchers and corporations.

With strong growth in key sectors but weakness in others, Plexus management faces a pivotal moment at the upcoming Raymond James investor conference.

BioNexus Gene Lab appoints Matthew Barsing to lead its Chemrex subsidiary, signaling a strategic overhaul from industrial chemicals to biotech and advanced tech.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

Montreal firm's advanced titanium powder will fuel next-gen aerospace innovation, highlighting its role in a critical, high-growth global market.